The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial

• Main Authors: Azwin Mengindra Putera, Azwin, Zahrah Hikmah, Zahrah, Anang Endaryanto, Anang, Irwanto, Irwanto, Margarita Maria Maramis, Margarita
• Format: Article PeerReviewed
• Language: English; Indonesian; English
• Published: Elsevier
• Subjects: R5-920 Medicine (General)
• Online Access: https://repository.unair.ac.id/124367/1/09.%20The%20role%20of%20house.pdf; https://repository.unair.ac.id/124367/2/C-9.pdf; https://repository.unair.ac.id/124367/3/09.%20The%20role%20of%20house%20dust%20mite%20immunotherapy%20in%20Indonesian.pdf; https://repository.unair.ac.id/124367/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988318/; https://doi.org/10.1016/j.heliyon.2021.e06510
• Institution: Universitas Airlangga

Abstract Background: Chronic rhinosinusitis allergy (CRA) is a disease that is commonly found in children and is mostly caused by allergy to house dust mites (HDM). The use of HDM immunotherapy can be considered in children with allergies. Objectives: Analyzing the impact of mite immunotherapy on disease burden in Indonesian children with CRA. Methods: A randomized control trial study was conducted to participants in 2 groups, namely the immunotherapy group (n = 25) and the non-immunotherapy group (n = 25). Participants were given HDM immunotherapy for 14 weeks, which was given once per week. Participants during therapy were evaluated for rhinosinusitis symptoms and measured their immunity status (specific IgE), sleep quality (SDSC), quality of life (SN5), and family coping (F-COPES) pre-post therapy. Statistical analysis used in this study included paired t-test, Wilcoxon test, independent t-test, or Mann Whitney test with p < 0.05. Results: The value of specific IgE in the immunotherapy group was 4.12 ± 7.75 kU/l (pre-test) and 1.52 ± 2.42 kU/l (post-test; p < 0.001), while in the non-immunotherapy group was 1.47 ± 3.28 kU/l (pre-test) and 1.18 ± 2.81 kU/l (post-test; p = 0.317). The SDSC value in the immunotherapy group was 42.16 ± 2.75 (pre-test) and 30.32 ± 3.22 (post-test; p < 0.001), while in the non-immunotherapy group was 41.92 ± 2.75 (pre-test) and 41.84 ± 2.87 (post-test; p = 0.987). The F-COPES value in the immunotherapy group was 101.56 ± 5.78 (pre-test) and 105.20 ± 4.31 (post-test; p = 0.015), while in the non-immunotherapy group was 100.36 ± 9.63 (pre-test) and 99.96 ± 9.98 (post-test; p = 0.224). The SN-5 value in the immunotherapy group was 30.04 ± 2.78 (pre-test) and 11.00 ± 2.33 (post-test; p < 0.001), while in the non-immunotherapy group was 30.04 ± 2.78 (pre-test) and 30.04 ± 2.78 (post-test; p = 0.767). There was a significant comparison between the immunotherapy group and the non-immunotherapy group on the specific IgE (p = 0.013), SDSC (p < 0.001), and SN-5 (p < 0.001) values. Meanwhile, there was no significant difference in the F-COPES value (p = 0.129). Conclusions: The administration of HDM immunotherapy can improve the participant's immunity, quality of life, and sleep disorder.